Listed

Intensity Therapeutics, Inc.

INTSNasdaqCIK 1567264HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$3.1m, Q2 FY2026
Net income−$3.0m, Q2 FY2026
Intensity Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$k1,352Research and development, Q3 FY2023, three months to 2023-09-30$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure1,801Research and development, Q4 FY2023, three months to 2023-12-31$1.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-13, accession 0001567264-25-000010. Derived: 12-month figure less the 9-month figure.Report this figure2,815Research and development, Q1 FY2024, three months to 2024-03-31$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure3,563Research and development, Q2 FY2024, three months to 2024-06-30$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure2,151Research and development, Q3 FY2024, three months to 2024-09-30$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure1,967Research and development, Q4 FY2024, three months to 2024-12-31$2.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-27, accession 0001567264-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure2,189Research and development, Q1 FY2025, three months to 2025-03-31$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure1,541Research and development, Q2 FY2025, three months to 2025-06-30$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure1,553Research and development, Q3 FY2025, three months to 2025-09-30$1.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure1,502Research and development, Q4 FY2025, three months to 2025-12-31$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-27, accession 0001567264-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure1,195Research and development, Q1 FY2026, three months to 2026-03-31$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure1,833Research and development, Q2 FY2026, three months to 2026-06-30$1.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure
Operating income$k(2,491)Operating income, Q3 FY2023, three months to 2023-09-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure(3,352)Operating income, Q4 FY2023, three months to 2023-12-31−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-13, accession 0001567264-25-000010. Derived: 12-month figure less the 9-month figure.Report this figure(4,743)Operating income, Q1 FY2024, three months to 2024-03-31−$4.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure(5,069)Operating income, Q2 FY2024, three months to 2024-06-30−$5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure(3,570)Operating income, Q3 FY2024, three months to 2024-09-30−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure(3,203)Operating income, Q4 FY2024, three months to 2024-12-31−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001567264-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure(3,394)Operating income, Q1 FY2025, three months to 2025-03-31−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure(2,705)Operating income, Q2 FY2025, three months to 2025-06-30−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure(2,733)Operating income, Q3 FY2025, three months to 2025-09-30−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure(3,140)Operating income, Q4 FY2025, three months to 2025-12-31−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001567264-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure(2,526)Operating income, Q1 FY2026, three months to 2026-03-31−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure(3,084)Operating income, Q2 FY2026, three months to 2026-06-30−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure
Interest expense$k0.0Interest expense, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure(0.2)Interest expense, Q4 FY2023, three months to 2023-12-31−$161. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-14, accession 0001628280-24-011207. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-09, accession 0001567264-24-000010.Report this figure0.0Interest expense, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-08-08, accession 0001567264-24-000041.Report this figure0.0Interest expense, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-03-13, accession 0001567264-25-000010. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(2,329)Net income, Q3 FY2023, three months to 2023-09-30−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure(3,172)Net income, Q4 FY2023, three months to 2023-12-31−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-13, accession 0001567264-25-000010. Derived: 12-month figure less the 9-month figure.Report this figure(4,603)Net income, Q1 FY2024, three months to 2024-03-31−$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure(4,971)Net income, Q2 FY2024, three months to 2024-06-30−$5.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure(3,513)Net income, Q3 FY2024, three months to 2024-09-30−$3.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure(3,181)Net income, Q4 FY2024, three months to 2024-12-31−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-27, accession 0001567264-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure(3,347)Net income, Q1 FY2025, three months to 2025-03-31−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure(2,537)Net income, Q2 FY2025, three months to 2025-06-30−$2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure(2,671)Net income, Q3 FY2025, three months to 2025-09-30−$2.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure(3,051)Net income, Q4 FY2025, three months to 2025-12-31−$3.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-27, accession 0001567264-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure(2,434)Net income, Q1 FY2026, three months to 2026-03-31−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure(3,007)Net income, Q2 FY2026, three months to 2026-06-30−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure
Diluted EPS$ per share(0.17)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figurenot reported(0.34)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure(0.36)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure(0.25)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figurenot reported(5.51)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$5.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure(3.36)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$3.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure(0.06)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figurenot reported(0.96)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.96 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure(1.11)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure
Basic EPS$ per share(0.17)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figurenot reported(0.34)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure(0.36)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure(0.25)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figurenot reported(5.51)Basic EPS, Q1 FY2025, three months to 2025-03-31−$5.51 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure(3.36)Basic EPS, Q2 FY2025, three months to 2025-06-30−$3.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure(0.06)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figurenot reported(0.96)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.96 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure(1.11)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure

Balance sheet

Cash and equivalents$9.5m, Q2 FY2026
Shareholders' equity$9.2m, Q2 FY2026
Intensity Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m6.7Cash and equivalents, Q3 FY2023, at 2023-09-30$6.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0001213900-23-085791.Report this figure8.6Cash and equivalents, FY2023, at 2023-12-31$8.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-13, accession 0001567264-25-000010.Report this figure7.5Cash and equivalents, Q1 FY2024, at 2024-03-31$7.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001567264-24-000010.Report this figure3.2Cash and equivalents, Q2 FY2024, at 2024-06-30$3.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001567264-24-000041.Report this figure2.8Cash and equivalents, Q3 FY2024, at 2024-09-30$2.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure2.6Cash and equivalents, FY2024, at 2024-12-31$2.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-27, accession 0001567264-26-000024.Report this figure0.9Cash and equivalents, Q1 FY2025, at 2025-03-31$929.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure2.2Cash and equivalents, Q2 FY2025, at 2025-06-30$2.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure7.1Cash and equivalents, Q3 FY2025, at 2025-09-30$7.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure11.9Cash and equivalents, FY2025, at 2025-12-31$11.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure10.2Cash and equivalents, Q1 FY2026, at 2026-03-31$10.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure9.5Cash and equivalents, Q2 FY2026, at 2026-06-30$9.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure
Current assets$m16.6Current assets, Q3 FY2023, at 2023-09-30$16.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0001213900-23-085791.Report this figure15.5Current assets, FY2023, at 2023-12-31$15.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-13, accession 0001567264-25-000010.Report this figure11.2Current assets, Q1 FY2024, at 2024-03-31$11.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001567264-24-000010.Report this figure7.4Current assets, Q2 FY2024, at 2024-06-30$7.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001567264-24-000041.Report this figure3.8Current assets, Q3 FY2024, at 2024-09-30$3.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure3.4Current assets, FY2024, at 2024-12-31$3.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-27, accession 0001567264-26-000024.Report this figure1.7Current assets, Q1 FY2025, at 2025-03-31$1.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure3.0Current assets, Q2 FY2025, at 2025-06-30$3.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure8.2Current assets, Q3 FY2025, at 2025-09-30$8.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure12.7Current assets, FY2025, at 2025-12-31$12.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure10.9Current assets, Q1 FY2026, at 2026-03-31$10.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure11.2Current assets, Q2 FY2026, at 2026-06-30$11.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure
Total assets$m16.8Total assets, Q3 FY2023, at 2023-09-30$16.8m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0001213900-23-085791.Report this figure17.3Total assets, FY2023, at 2023-12-31$17.3m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-13, accession 0001567264-25-000010.Report this figure12.4Total assets, Q1 FY2024, at 2024-03-31$12.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001567264-24-000010.Report this figure8.7Total assets, Q2 FY2024, at 2024-06-30$8.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001567264-24-000041.Report this figure5.2Total assets, Q3 FY2024, at 2024-09-30$5.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure4.8Total assets, FY2024, at 2024-12-31$4.8m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-27, accession 0001567264-26-000024.Report this figure3.1Total assets, Q1 FY2025, at 2025-03-31$3.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure4.4Total assets, Q2 FY2025, at 2025-06-30$4.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure9.6Total assets, Q3 FY2025, at 2025-09-30$9.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure14.1Total assets, FY2025, at 2025-12-31$14.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure12.3Total assets, Q1 FY2026, at 2026-03-31$12.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure11.5Total assets, Q2 FY2026, at 2026-06-30$11.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure
Current liabilities$m0.7Current liabilities, Q3 FY2023, at 2023-09-30$724.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0001213900-23-085791.Report this figure4.0Current liabilities, FY2023, at 2023-12-31$4.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-13, accession 0001567264-25-000010.Report this figure2.5Current liabilities, Q1 FY2024, at 2024-03-31$2.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001567264-24-000010.Report this figure3.2Current liabilities, Q2 FY2024, at 2024-06-30$3.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001567264-24-000041.Report this figure2.3Current liabilities, Q3 FY2024, at 2024-09-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure1.8Current liabilities, FY2024, at 2024-12-31$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-27, accession 0001567264-26-000024.Report this figure2.6Current liabilities, Q1 FY2025, at 2025-03-31$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure2.2Current liabilities, Q2 FY2025, at 2025-06-30$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure2.3Current liabilities, Q3 FY2025, at 2025-09-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure2.1Current liabilities, FY2025, at 2025-12-31$2.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure2.2Current liabilities, Q1 FY2026, at 2026-03-31$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure2.2Current liabilities, Q2 FY2026, at 2026-06-30$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure
Total liabilities$m0.9Total liabilities, Q3 FY2023, at 2023-09-30$904.9k. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0001213900-23-085791.Report this figure4.1Total liabilities, FY2023, at 2023-12-31$4.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-13, accession 0001567264-25-000010.Report this figure2.7Total liabilities, Q1 FY2024, at 2024-03-31$2.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001567264-24-000010.Report this figure3.3Total liabilities, Q2 FY2024, at 2024-06-30$3.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001567264-24-000041.Report this figure2.4Total liabilities, Q3 FY2024, at 2024-09-30$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure1.9Total liabilities, FY2024, at 2024-12-31$1.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-27, accession 0001567264-26-000024.Report this figure2.7Total liabilities, Q1 FY2025, at 2025-03-31$2.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure2.3Total liabilities, Q2 FY2025, at 2025-06-30$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure2.4Total liabilities, Q3 FY2025, at 2025-09-30$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure2.2Total liabilities, FY2025, at 2025-12-31$2.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure2.3Total liabilities, Q1 FY2026, at 2026-03-31$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure2.3Total liabilities, Q2 FY2026, at 2026-06-30$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure
Shareholders' equity$m15.9Shareholders' equity, Q3 FY2023, at 2023-09-30$15.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure13.2Shareholders' equity, FY2023, at 2023-12-31$13.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-27, accession 0001567264-26-000024.Report this figure9.7Shareholders' equity, Q1 FY2024, at 2024-03-31$9.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure5.3Shareholders' equity, Q2 FY2024, at 2024-06-30$5.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure2.8Shareholders' equity, Q3 FY2024, at 2024-09-30$2.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure2.9Shareholders' equity, FY2024, at 2024-12-31$2.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure0.3Shareholders' equity, Q1 FY2025, at 2025-03-31$334.0k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure2.2Shareholders' equity, Q2 FY2025, at 2025-06-30$2.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure7.2Shareholders' equity, Q3 FY2025, at 2025-09-30$7.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure11.9Shareholders' equity, FY2025, at 2025-12-31$11.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure10.0Shareholders' equity, Q1 FY2026, at 2026-03-31$10.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure9.2Shareholders' equity, Q2 FY2026, at 2026-06-30$9.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure

Cash flow

Operating cash flow−$2.3m, Q2 FY2026
Intensity Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(5,119)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001567264-24-000052. Derived: 9-month figure less the 6-month figure.Report this figure(946)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$946.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-13, accession 0001567264-25-000010. Derived: 12-month figure less the 9-month figure.Report this figure(4,366)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure(4,214)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$4.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001567264-25-000077. Derived: 6-month figure less the 3-month figure.Report this figure(3,972)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001567264-25-000103. Derived: 9-month figure less the 6-month figure.Report this figure(2,668)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$2.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001567264-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure(1,989)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure(2,456)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001567264-26-000059. Derived: 6-month figure less the 3-month figure.Report this figure(2,387)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001567264-25-000103. Derived: 9-month figure less the 6-month figure.Report this figure(2,401)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001567264-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure(1,826)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure(2,340)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001567264-26-000059. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)2.71m, Q2 FY2026
Intensity Therapeutics, Inc., shares, quarterly
Line itemUnitperiod not labelled2022-09-30period not labelled2023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares3.4Diluted shares (weighted), period not labelled, three months to 2022-09-303,410,103 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0001213900-23-085791.Report this figure3.4Diluted shares (weighted), period not labelled, three months to 2023-03-313,410,103 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001567264-24-000010.Report this figure3.5Diluted shares (weighted), Q2 FY2023, three months to 2023-06-303,516,579 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001567264-24-000041.Report this figure13.7Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3013,660,627 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001567264-24-000052.Report this figure13.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3113,709,487 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001567264-25-000039.Report this figure13.7Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3013,712,152 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001567264-25-000077.Report this figure13.8Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3013,804,651 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure0.6Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31606,928 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure0.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30754,725 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure43.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3043,042,691 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001567264-25-000103.Report this figure2.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-312,533,918 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001567264-26-000046.Report this figure2.7Diluted shares (weighted), Q2 FY2026, three months to 2026-06-302,706,607 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure

Shares outstanding: 3.26mShares outstanding, period not labelled, at 2026-08-073,264,879 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001567264-26-000059.Report this figure at Aug 7, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. Listed shows no prices and gives no investment advice.